Brookline Capital Management Forecasts MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Stock analysts at Brookline Capital Management increased their Q1 2025 earnings per share estimates for Monopar Therapeutics in a research note issued on Wednesday, February 5th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of ($0.68) per share for the quarter, up from their prior estimate of ($0.78). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS and FY2025 earnings at ($3.54) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

MNPR has been the topic of a number of other research reports. Piper Sandler initiated coverage on Monopar Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $72.00 price target on the stock. HC Wainwright upped their target price on Monopar Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd.

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $51.89 on Monday. Monopar Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $54.30. The firm has a market capitalization of $316.53 million, a price-to-earnings ratio of -26.34 and a beta of 1.30. The stock’s 50-day simple moving average is $29.40 and its 200-day simple moving average is $15.56.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.